Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

We previously identified matrix metalloproteinase 2 (MMP2) and MMP9 plasma levels as candidate biomarkers of bevacizumab activity in patients with recurrent glioblastoma. The aim of this study was to assess the predictive value of MMP2 and MMP9 in a randomized phase III trial in patients with newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiguet-Jiglaire, Carine, Boissonneau, Sebastien, Denicolai, Emilie, Hein, Victoria, Lasseur, Romain, Garcia, Josep, Romain, Sylvie, Appay, Romain, Graillon, Thomas, Mason, Warren, Carpentier, Antoine F., Brandes, Alba A., Ouafik, L.’Houcine, Wick, Wolfgang, Baaziz, Ania, Gigan, Julien P., Argüello, Rafael J., Figarella-Branger, Dominique, Chinot, Olivier, Tabouret, Emeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722051/
https://www.ncbi.nlm.nih.gov/pubmed/34980260
http://dx.doi.org/10.1186/s40478-021-01305-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722051/
https://www.ncbi.nlm.nih.gov/pubmed/34980260
http://dx.doi.org/10.1186/s40478-021-01305-4

Ejemplares similares